Sterculic acid, a stearoyl-CoA desaturase-1 (SCD1) inhibitor, effectively suppresses delta-9 desaturase (Δ9D) activity in a dose-dependent manner, exhibiting an inhibition concentration (IC50) value of 0.9 μM [1].

Sterculic acid (SA), a cyclopropene fatty acid derived from Sterculia foetida seeds, exhibits diverse biological activities, including the reduction of adrenomedullin expression (AP, RP, APS, IML, in preparation) and mediating anti-inflammatory and protective effects. It also demonstrates a potent luteolytic effect in ovines by inhibiting progesterone synthesis, leading to luteal regression [2].

Sterculic acid is suggested as a promising intervention for metabolic syndrome (MS), as it effectively inhibits the function of stearoyl-CoA desaturase-1 (SCD1) in vivo [3].